We sat down with Pietro Allegrini, R&D Director at Indena, to discuss their recent strategic investments in the CDMO space. Pietro shares insights into Indena’s advancements in highly potent compounds, cutting-edge technologies, and their latest developments in ADC activities. He also talks about the expanding capacities and the company’s commitment to innovation in the pharmaceutical industry. Stay tuned for an in-depth look at how Indena is shaping the future of biopharmaceutical development.
TWENTYFOURSEVENBIOPHARMA